An international leader in pharmaceuticals, Pfizer announced this week a partnership with Saama Technologies, a California-based Life Sciences AI firm. Neither company currently owns any published patents in the AI Biotech sector.
Pfizer will be using Saama's Life Science Analytics Cloud (LSAC) platform, which is AI based, to analyze clinical trial models. The companies hope this partnership will enable Pfizer to more quickly bring drugs to the market. It is entirely possible that this partnership, especially given the size of Pfizer's overall IP portfolio, could lead to IP for new medical diagnostic methods as well.
Last May, Saama raised $40 million to support growth of its LSAC platform. Saama has existing partnerships with many life sciences Celgene, Gilead, and Roche.
Artificial intelligence and human health don’t stop with our general diagnostics, cardiology, neurology, and activity sectors. This sector covers AI/ML-centric advancements in auditory, dental, GI/hepatic, circulatory, immune, musculoskeletal, ocular, reproductive, respiratory, dermatological, urinary, rectal, and spectrometry related biotech.
View Patent Forecast®
Top Corporations
News and Insights
Data Visualization
Artificial intelligence and human health don’t stop with our general diagnostics, cardiology, neurology, and activity sectors. This sector covers AI/ML-centric advancements in auditory, dental, GI/hepatic, circulatory, immune, musculoskeletal, ocular, reproductive, respiratory, dermatological, urinary, rectal, and spectrometry related biotech.